tetano
Editor, Senior Moderator
NPJ Vaccines
. 2024 Apr 8;9(1):75.
doi: 10.1038/s41541-024-00861-9. Recovery from antibody-mediated biliary ductopenia and multiorgan inflammation after COVID-19 vaccination
Alan Chang[SUP] 1 2 [/SUP], Yung-Ming Jeng[SUP] 3 [/SUP], Cheng-Maw Ho[SUP] 4 5 [/SUP], Po-Huang Lee[SUP] 2 6 [/SUP]
Affiliations
The coronavirus disease 2019 (COVID-19) pandemic has caused significant morbidity and mortality. Spike messenger RNA (mRNA)-based vaccines against severe acute respiratory syndrome coronavirus 2 may contribute to immune-mediated injuries. Here we present a case of a previously healthy 47-year-old man, who developed progressive jaundice 2 weeks after receiving his 3[SUP]rd[/SUP] COVID-19 vaccination (1[SUP]st[/SUP] mRNA-based vaccine). Apart from elevated serum total bilirubin levels (peaked at >70 mg/dL), deteriorating renal (blood urea nitrogen: peak, 108.5 mg/dL; creatinine: peak, 6 mg/dL) and exocrine pancreas (amylase: peak, 1717 U/L; lipase: peak, 5784 U/L) profiles were also seen. Vanishing bile duct syndrome characterized by ductopenia and cholangiocyte vacuolation, positive C4d deposition, and high titer of anti-angiotensin II type 1 receptor antibody consistently explain the overall antibody-mediated pathogenesis resembling antibody-mediated "rejection" in the solid organ transplant setting. Corticosteroids and plasmapheresis were administered, leading to gradual resolution of the symptoms, and the jaundice completely resolved 2 months later. In conclusion, we reported a case of antibody-mediated multiorgan injury after an mRNA COVID-19 vaccine, characterized by severe cholangiopathy. The patient recovered with corticosteroids and plasmapheresis, and long-term follow-up is necessary.
. 2024 Apr 8;9(1):75.
doi: 10.1038/s41541-024-00861-9. Recovery from antibody-mediated biliary ductopenia and multiorgan inflammation after COVID-19 vaccination
Alan Chang[SUP] 1 2 [/SUP], Yung-Ming Jeng[SUP] 3 [/SUP], Cheng-Maw Ho[SUP] 4 5 [/SUP], Po-Huang Lee[SUP] 2 6 [/SUP]
Affiliations
- PMID: 38589436
- PMCID: PMC11001909
- DOI: 10.1038/s41541-024-00861-9
The coronavirus disease 2019 (COVID-19) pandemic has caused significant morbidity and mortality. Spike messenger RNA (mRNA)-based vaccines against severe acute respiratory syndrome coronavirus 2 may contribute to immune-mediated injuries. Here we present a case of a previously healthy 47-year-old man, who developed progressive jaundice 2 weeks after receiving his 3[SUP]rd[/SUP] COVID-19 vaccination (1[SUP]st[/SUP] mRNA-based vaccine). Apart from elevated serum total bilirubin levels (peaked at >70 mg/dL), deteriorating renal (blood urea nitrogen: peak, 108.5 mg/dL; creatinine: peak, 6 mg/dL) and exocrine pancreas (amylase: peak, 1717 U/L; lipase: peak, 5784 U/L) profiles were also seen. Vanishing bile duct syndrome characterized by ductopenia and cholangiocyte vacuolation, positive C4d deposition, and high titer of anti-angiotensin II type 1 receptor antibody consistently explain the overall antibody-mediated pathogenesis resembling antibody-mediated "rejection" in the solid organ transplant setting. Corticosteroids and plasmapheresis were administered, leading to gradual resolution of the symptoms, and the jaundice completely resolved 2 months later. In conclusion, we reported a case of antibody-mediated multiorgan injury after an mRNA COVID-19 vaccine, characterized by severe cholangiopathy. The patient recovered with corticosteroids and plasmapheresis, and long-term follow-up is necessary.